A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy.
Detecting mutation in BRCA1/2 is a generally accepted strategy for screening ovarian cancers that have impaired homologous recombination (HR) ability and improved sensitivity to PARP inhibitor. However, a substantial subset of BRCA-mutant ovarian cancer patients shows less impaired or unimpaired HR...
Saved in:
| Main Authors: | Shaojun Zhang, Yuan Yuan, Dapeng Hao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0113169&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of outcomes of neoadjuvant chemotherapy in BRCA1- versus BRCA2-associated breast and ovarian cancers
by: Anna Sokolenko, et al.
Published: (2025-06-01) -
BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer
by: Heidelinde Fiegl, et al.
Published: (2024-11-01) -
Ovarian cancer and BRCA mutation genetic testing: the Brazilian reality
by: Dalila Cunha de Oliveira, et al.
Published: (2021-10-01) -
RESPONSE TO NEOADYAVANT CHEMOTHERAPY WITH PLATINUM-BASED DRUGS IN BREAST CANCER PATIENTS WITH BRCA1 DELETION IN TUMOR
by: M. M. Tsyganov, et al.
Published: (2019-06-01) -
OVARIAN CANCER IN PATIENTS WITH BRCA1 5382insC MUTATION
by: А. B. Villert, et al.
Published: (2016-02-01)